/MNPR

Monopar Therapeutics Inc

MNPR

$110.26USD↑+0.27%+0.30 today

MARKET CAP

740.1M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$110 – $114

52W RANGE

$43

$125

AI Summary

Stalk

StalkMedium

MNPR remains in a sustained uptrend above its 50- and 200-day SMAs, but is consolidating in a descending triangle beneath the $115 resistance and below the short-term EMAs. Volume contraction and neutral momentum argue for patience. Entries should be deferred until price either proves support near the 50-day SMA around $102 or shows clear breakout and acceptance above the $115–$113 zone.

↑Pending ALXN1840 NDA targets Wilson disease approval catalyst
↑Rising 13F ownership indicates strong institutional support
↓Negative earnings yield and cash burn raise valuation concerns

Full analysis →

Buying

3

institutions

Selling

4

institutions

New Positions

0

this quarter

Filing Period

Q1 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
JH Janus Henderson Group Plc Q1 2026	BUY	2.63 M	144.12 M	+1.32 M	+67.8%	0.04%
BI Blackrock, Inc. Q2 2026	BUY	348.82 K	32.30 M	+32.25 K	+86.2%	0.00%
AC Adar1 Capital Management, LLC Q2 2026	SELL	217.59 K	20.15 M	+-46.68 K	+39.1%	0.93%
BA Balyasny Asset Management L.P. Q2 2026	SELL	134.54 K	12.46 M	+-1.90 K	+66.6%	0.02%
MM Millennium Management LLC Q2 2026	SELL	50.31 K	4.66 M	+-2.64 K	+60.6%	0.00%
CA Citadel Advisors LLC Q2 2026	SELL	37.00 K	3.43 M	+-21.43 K	+7.0%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	2.51 K	236.97 K	+84.00	+83.6%	0.00%